Personalis, Inc.
NASDAQ:PSNLMedical - Diagnostics & Research
+$0.34 today
- Market cap
- $1.62B
- Beta
- 2.28
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$0.92
Volume 1.47M
Average 2.31M
PSNL Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Personalis, Inc.NASDAQ: PSNL
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $15.19M rose 13.4% year over year, ahead of the -2.6% change in trailing-twelve-month cost of revenue. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at +1.4% a year.
Context
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +13.4% holds above the trailing-twelve-month pace of -2.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 53.87M USD
- Year-over-year change
- -6.8%
- 4-year CAGR
- +0.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.87M | -6.8% |
| FY2024 | 2024-12-31 | 57.79M | +4.6% |
| FY2023 | 2023-12-31 | 55.27M | +6.9% |
| FY2022 | 2022-12-31 | 51.7M | -4.0% |
| FY2021 | 2021-12-31 | 53.84M | — |
Cost of Revenue vs competitors
How PSNL compares with its peers on the latest reported figures
- PSNL's LTM Mar 2026 cost of revenue of $55.67M is the lowest of the 10 companies compared; the peer median is $196.33M.
- Its year-over-year change of -2.6% is the 9th highest of 10, against a peer median of +13.2%.
- Cost of revenue amounts to 86.3% of revenue for PSNL, versus a peer median of 34.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $939.25M | +28.9% | +21.1% | 34.7% | |
| LTM Sep 2026 | $445.18M | +36.1% | +30.7% | 34.8% | |
| LTM Jun 2026 | $437.4M | +13.2% | +11.4% | 57.1% | |
| LTM Mar 2026 | $249M | -0.1% | +7.1% | 30.0% | |
| LTM Mar 2026 | $196.33M | +9.7% | -8.7% | 61.3% | |
| LTM Jun 2026 | $183.16M | -12.9% | +6.8% | 110.8% | |
| LTM Jun 2026 | $156.8M | +3.1% | +15.6% | 27.9% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $144.53M | +21.5% | -20.9% | 31.8% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $114.19M | +39.8% | — | 28.7% |
| LTM Mar 2026 | $55.67M | -2.6% | +1.4% | 86.3% | |
| Peer median (excluding PSNL) | $196.33M | +13.2% | +9.2% | 34.7% | |
Competitors are the stored peer set for PSNL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 85.49M | 65.05M | 73.48M | 84.61M | 0 |
| Cost of Revenue | 53.84M | 51.7M | 55.27M | 57.79M | 53.87M |
| Gross Profit | 31.66M | 13.35M | 18.21M | 26.83M | (53.87M) |
| Gross Margin | 37.0% | 20.5% | 24.8% | 31.7% | — |
| Research & Development | 49.31M | 64.91M | 64.78M | 48.91M | 50.26M |
| Selling, General & Admin | 47.7M | 63.97M | 49.73M | 46.19M | 53.57M |
| Operating Expenses | 97.01M | 128.88M | 128.14M | 95.09M | 34.19M |
| Depreciation & Amortization | 6.01M | 8.43M | 11.3M | 10.94M | 10.05M |
| EBITDA | (59.01M) | (104.64M) | (96.81M) | (70.3M) | (71M) |
| EBITDA Margin | -69.0% | -160.9% | -131.7% | -83.1% | — |
| Operating Income | (65.35M) | (115.53M) | (109.94M) | (68.27M) | (88.06M) |
| Operating Margin | -76.4% | -177.6% | -149.6% | -80.7% | — |
| Interest Income | 367K | 2.4M | 5.9M | 5.51M | 7.16M |
| Interest Expense | 184K | 201K | 110K | 24K | 205K |
| Other Income / Expenses | 141K | 2.26M | 1.72M | (13M) | 6.81M |
| Income Before Tax | (65.21M) | (113.28M) | (108.21M) | (81.27M) | (81.25M) |
| Pre-Tax Margin | -76.3% | -174.1% | -147.3% | -96.0% | — |
| Income Tax Expense | 14K | 40K | 83K | 18K | 21K |
| Net Income | (65.23M) | (113.32M) | (108.3M) | (81.28M) | (81.27M) |
| Net Margin | -76.3% | -174.2% | -147.4% | -96.1% | — |
| EPS (Basic) | (1.49) | (2.48) | (2.25) | (1.37) | (0.91) |
| EPS (Diluted) | (1.49) | (2.48) | (2.25) | (1.37) | (0.91) |
| Weighted Avg Shares | 43.89M | 45.7M | 48.18M | 59.25M | 89.24M |
| Weighted Avg Shares (Diluted) | 43.89M | 45.7M | 48.18M | 59.25M | 89.24M |
Personalis, Inc.
NASDAQ:PSNL
Intrinsic Alpha fair value
Locked
Current Price
$14.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.